---
title: "Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Economic impact of diagnostic testing"
description: "Formulary evidence on Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Economic impact of diagnostic testing. Topics: Cost of predictive genetic testing at HDSA Centers of Excellence in the United States, Predictive testing uptake among at-risk individuals, Fear of health insurance loss and out-of-pocket payment for testing: North America, Insurance protections for genetic information in the United States, and 4 further topics. 8 evidence topics quoted from 10 sources."
canonical: "https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description/economic-impact-of-diagnostic-testing"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Economic impact of diagnostic testing

<a id="heading-2.2.1.8.4"></a>

## 2.2.1.8.4 Economic Impact of Diagnostic Testing

<a id="topic-2.2.1.8.4-1"></a>

### Cost of predictive genetic testing at HDSA Centers of Excellence in the United States

> “As of 2019 there were 47 HDSA COE’s in the US, and in the preceding year, they performed HD predictive genetic testing on a total of 777 individuals.”
> “The average cost of these tests was $1,157.12, with a range of $275-3,640 (Figure 1).”
> “The average cost for the various components of the predictive testing process included: $199.80 for genetic counselling, $278.40 for psychology, $666.33 for neuropsychology, $317.50 for neurology, $52.83 for social work, $352.80 for gene testing, and $210.80 for miscellaneous fees (Figure 2).”
> “59.6% of COE’s covered the cost of some component of the testing process out of COE grant funds, and 57.5% offered other financial assistance to offset the cost of the testing process.”

Source: [Massey et al. (2021)](https://www.mdsabstracts.org/abstract/cost-of-predictive-genetic-testing-for-huntingtons-disease-at-centers-of-excellence-in-the-us/)

<a id="topic-2.2.1.8.4-2"></a>

### Predictive testing uptake among at-risk individuals

> “9407 predictive tests were performed across 23 UK centres.”
> “Using a prevalence figure of 12.3 × 10−5, the cumulative uptake of predictive testing in the 50% at-risk UK population from 1994 to 2014 was estimated at 17.4% (95% CI: 16.9–18.0%).”
> “Future therapies in HD will likely target presymptomatic individuals; therefore, identifying the at-risk population whose gene status is unknown is of significant public health value.”

Source: [Baig et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5027682/)

> “The uptake of predictive testing in the entire HD 50% at-risk population in 2001 was calculated by three methods giving a range of 12.3-14.6%. Uptake after 20 years was estimated to be 14.7%.”

Source: [Morrison et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/20880124/)

<a id="topic-2.2.1.8.4-3"></a>

### Fear of health insurance loss and out-of-pocket payment for testing: North America

> “After enrollment, 83 individuals [8.3%] pursued genetic testing. Their greatest concern was losing health insurance, and 41.6% of them [vs. 6.7% of those who did not pursue testing; P < 0.001] reported paying out of pocket for testing or other medical services to conceal their genetic risk from their insurer/employer.”
> “Among individuals who were tested, more United States residents [46.1%] than Canadian residents [0.0%; P = 0.02] paid out of pocket for health services or genetic testing.”

Source: [Oster et al. (2008)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2574833/)

<a id="topic-2.2.1.8.4-4"></a>

### Insurance protections for genetic information in the United States

> “GINA prohibits group health plans, individual and group health insurance companies, and Medicare issuers from:”
> “GINA only provides for protection under health insurance and Medicare. Issuers of other types of insurance, such as long term care insurance, disability insurance, and life insurance may still request genetic information to determine eligibility and other coverage terms.”
> “Under GINA, an individual’s genetic test result is protected; however, health plans are permitted to use information about an individual’s disease when the disease has manifested.”

Source: [Huntington's Disease Society of America genetic testing and your rights](https://hdsa.org/find-help/healthcare-and-future-planning/genetic-testing-and-your-rights/)

<a id="topic-2.2.1.8.4-5"></a>

### Access costs: travel, time away from work, and counseling

> “Distance is a structural barrier, and relates to the time and travel required to access PT, the financial and other opportunity costs associated with taking time away from work and family to attend appointments and the stress of navigating urban centers.”

Source: [Hawkins et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3548262/)

> “Genetic counseling is necessary for presymptomatic or symptomatic HD genetic testing, but the lack of access to counseling because of geography or expense is a critical gap for many patients.”
> “The main advantage of tele-GC was reduction in travel time for both in-person GC first (n = 16) and tele-GC first (n = 11) participants.”

Source: [Hall et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11515112/)

<a id="topic-2.2.1.8.4-6"></a>

### Testing decisions when genetic services are fully funded: Israel

> “This pattern persists even when economic barriers are removed, demonstrating that psychological factors remain primary determinants of testing uptake.”

Source: [Inbar et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13379509/)

<a id="topic-2.2.1.8.4-7"></a>

### Demand for predictive testing after therapeutic trial news

> “the demand for predictive testing in at risk individuals significantly increased following the press release reporting the successful completion of the Ionis-HTTRx (RG 6042) trial.”

Source: [Bardakjian et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31381522/)

<a id="topic-2.2.1.8.4-8"></a>

### Reproductive genetic testing: cost-effectiveness of preimplantation genetic testing

> “Cost-effectiveness analysis in a theoretical cohort of 3,851 couples, where one individual is heterozygous for Huntington disease.”
> “In vitro fertilization preimplantation genetic testing was associated with 77 more QALYs and a cost savings of $46,394,268.”
> “Most notably, in our theoretical cohort of couples, IVF preimplantation genetic testing resulted in 1,079 fewer Huntington disease-affected offspring.”

Source: [Christensen et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35618525/)

## Related pages
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Terms and abbreviations](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations.md)
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Product information and disease description](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Clinical evidence](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Economic information and modeling report](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: References](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references.md)
